Eli Lilly & Co. (LLY) – General News
-
Midday movers: Travelers, JB Hunt fall; United Airlines rises
-
Lilly partners with Amazon to deliver Zepbound and other drugs
-
FDA to delay decision on Eli Lilly Alzheimer's drug for second time
-
Midday movers: Victoria's Secret, Nordstrom fall; OneSpan, Novo Nordisk rise
-
Bank of America analysts raise Eli Lilly price target amid obesity drug optimism
-
Midday movers: Palantir and Spotify surge, and more
-
Midday movers: Estee Lauder, Eli Lilly and more
-
As Lilly rivalry flares, Novo CEO sets out Wegovy launch strategy
-
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
-
Weight loss drug windfall attracts pharma companies
-
Midday movers: Apple, Tesla, Eli Lilly and more
-
US diabetes patients face delays as insurers tighten Ozempic coverage
-
Midday movers: Macy’s, Broadcom, Eli Lilly and more
-
Eli Lilly obesity drug now available in US pharmacies
-
Lilly to build $2.5 billion Germany plant as obesity drug demand soars
-
Retail investors crowd into Eli Lilly after weight-loss drug approval
-
Gap, Ross Stores, Fisker rise premarket; BJs Wholesale, ChargePoint fall
-
Eli Lilly extends tender offer to buy Point Biopharma after low participation
-
Walmart, Alibaba, Cisco stock fall premarket; Macy's, Catalent rise
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.47%
-
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
-
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
-
Starbucks, DoorDash, Roku, Qualcomm rise premarket; Peloton, Moderna fall
-
Apple earnings, Eli Lilly, ConocoPhillips: 3 things to watch
-
Futures higher, HSBC share buybacks, Evergrande reprieve - what's moving markets
-
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
-
Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
-
Small business optimism, Eli Lilly, UPS: 3 things to watch
-
Experimental drug works best for Alzheimer's patients treated as early as possible
-
S&P 500 off highs on Citigroup slip as major Wall Street banks kick off earnings
-
Eli Lilly to buy Versanis for up to $1.93 billion in obesity drugs push
-
Midday movers: Advanced Micro Devices, Eli Lilly, Estée Lauder and more
-
U.S. stocks are rising as investors await Fed's interest rate decision
-
AMD, Starbucks, Estée Lauder fall premarket; Eli Lilly, Kraft Heinz rise
-
Eli Lilly to invest additional $1.6 billion in 2 new plants
-
Altimmune shares plunge amid health concerns over obesity drug
-
Lilly to cut some list prices by 70% and offer $25 insulin
-
Midday movers: Meta Platforms, Align Technology, UnitedHealth Group and more
-
Eli Lilly's weak diabetes drugs sales cloud 2023 profit forecast
-
FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
-
Midday Movers: Uber Technologies, Intuit, Abiomed and More
-
Uber, Pfizer, Tesla, Carvana Rise Premarket; Eli Lilly Falls
-
Exclusive-U.S. finds new quality problems at Lilly drug factory
-
Midday Movers: Biogen, Apple, DocuSign and More
-
Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly
-
Eli Lilly to supply additional doses of COVID antibody drug to U.S.
-
Experimental Lilly drug neutralizes Omicron in lab; slightly higher risk of diabetes seen in kids after COVID
-
Eli Lilly signs deals to boost supply of COVID-19 treatment in India
-
Lilly-Vir's COVID-19 antibody combo reduces viral load in study
-
Europe begins rolling review of Eli Lilly's antibodies for COVID-19
Back to LLY Stock Lookup
